Savolitinib Heads for Phase III Trial in PRCC [News in Brief]

MET inhibitor shows promise treating papillary renal cell carcinoma in patients with abnormalities in MET signaling pathway.

from Cancer via ola Kala on Inoreader http://ift.tt/2tIsocY
via IFTTT